Mabtas N 100mg Injection
By Mabtas N
Rx
10ml Injection in a Vial

Composition
Rituximab(100mg)

Manufacturer - Intas Pharmaceuticals Ltd
Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India.

Expires on or after
July, 2025

liver
Limited information is available on the use of Mabtas N 100mg Injection in patients with liver disease. It is advisable to consult your doctor before using this medication. It is not recommended to use Mabtas N 100mg Injection in patients with active liver disease or a history of viral hepatitis, as it may lead to reactivation of the infection. Careful consideration and medical advice are essential before starting treatment with Mabtas N 100mg Injection in individuals with liver issues.

kidney
Mabtas N 100mg Injection may be safe for use in patients with kidney disease. Limited data suggests no dose adjustment may be necessary. Consult your doctor for guidance.

alcohol
Caution is advised when consuming alcohol with Mabtas N 100mg Injection. It is recommended to consult your doctor regarding alcohol consumption.

driving
When using Mabtas N 100mg Injection, it is unclear if it impacts driving ability. Avoid driving if you have any symptoms that hinder focus or reaction time.

pregnancy
Mabtas N 100mg Injection may not be safe to use during pregnancy. Animal studies have shown harmful effects on the developing baby. Your doctor will consider the benefits and risks before prescribing this medication. Please consult your doctor before using.

breastfeeding
Mabtas N 100mg Injection is considered safe during breastfeeding. Evidence shows no significant risk to the baby.
Habit Forming | No |
Chemical Class | Monoclonal Antibody |
Therapeutic Class | - |
Action Class | CD 20 Inhibitor |
₹7389.38
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 01-Oct-2024